-

Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers

Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for the company’s lead product candidate, TGN-S11, for the treatment of HPV-induced cancers.

“The acceptance of the TGN-S11 IND is an important milestone for Toragen, as we work toward a treatment for HPV-induced cancers,” said Sandra Coufal, MD, Toragen’s CEO. “We are now turning our focus to clinical execution with the commencement of our Phase 1 clinical trial and look forward to beginning to dose patients by mid-2023.”

The Phase 1 clinical trial is a dose escalation trial as well as a dose expansion trial in combination with a checkpoint inhibitor for patients with HPV-induced cancers.

About Toragen

Toragen, Inc. is targeting the root cause of virally induced cancers. https://toragen.com.

Contacts

Toragen, Inc.
Cheryl Collett
CFO
ccollett@toragen.com

Toragen, Inc.


Release Versions

Contacts

Toragen, Inc.
Cheryl Collett
CFO
ccollett@toragen.com

More News From Toragen, Inc.

Toragen, Inc. Provides Update on Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® in Patients with Stage 4 HPV-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from its Phase 1 trial of TGN-S11, a small molecule inhibitor of the human papillomavirus (HPV) E5 oncogene protein, in patients with cancers associated with HPV. This Phase 1 trial was an open-label, non-randomized study in multiple cohorts of patients with relapsed, resistant,...

Toragen, Inc. Provides Update on Data from Ongoing Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® (pembrolizumab) in Patients with Stage 4 Human Papillomavirus-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc. provides update on data from its ongoing Phase 1 Clinical Trial of TGN-S11 in patients with Stage 4 HPV-associated cancers....

Toragen, Inc. Announced Positive Safety Data Update from Cohort 2 and the Initiation of its Dose Expansion of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 2 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being co...
Back to Newsroom